Searched over 200M research papers for "lipoprotein definition"
10 papers analyzed
These studies suggest that lipoproteins are complex macromolecules involved in cholesterol transport and cardiovascular risk, with lipoprotein(a) specifically being a genetically determined risk factor for atherosclerotic diseases and stroke.
20 papers analyzed
Lipoproteins are spherical macromolecular complexes essential for the transport of hydrophobic molecules such as triglycerides and cholesteryl esters within the body. These complexes are enveloped by a monolayer of amphipathic molecules, including phospholipids, free cholesterol, and apoproteins. The primary classes of lipoproteins include chylomicrons, very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL), each playing distinct roles in lipid transport and metabolism.
Lipoprotein(a) [Lp(a)] is a specialized form of LDL that includes an additional protein called apolipoprotein(a) [apo(a)] bound to its surface apolipoprotein B100 . This unique structure distinguishes Lp(a) from other lipoproteins and contributes to its complex role in cardiovascular health. Lp(a) is known for its atherogenic properties, meaning it can promote the formation of fatty deposits in arteries, leading to cardiovascular diseases such as atherosclerosis and calcific aortic stenosis .
The levels of Lp(a) in the plasma are highly heritable and can vary significantly among individuals, with genetic factors accounting for approximately 70% to 90% of this variability . The gene encoding apo(a) on chromosome 6 plays a crucial role in determining Lp(a) levels, and variations in this gene can lead to significant differences in Lp(a) concentrations among different populations .
Elevated levels of Lp(a) are recognized as an independent risk factor for cardiovascular diseases, including myocardial infarction, stroke, and aortic valve stenosis . The risk associated with high Lp(a) levels is independent of other lipid markers, making it a critical factor in cardiovascular risk assessment . Current clinical guidelines recommend measuring Lp(a) levels in individuals with a family history of premature cardiovascular disease, familial hypercholesterolemia, or calcific aortic valve stenosis.
Despite the established role of Lp(a) in cardiovascular risk, effective treatments to lower Lp(a) levels are limited. Traditional lipid-lowering therapies such as statins and lifestyle modifications have minimal impact on Lp(a) levels. However, emerging therapies, including antisense oligonucleotides and small interfering RNA, show promise in significantly reducing Lp(a) levels and potentially improving cardiovascular outcomes.
Lipoproteins, particularly Lp(a), play a crucial role in lipid transport and cardiovascular health. Understanding the structure, genetic determinants, and clinical implications of Lp(a) is essential for developing effective strategies to manage cardiovascular risk. As research progresses, new therapies targeting Lp(a) may offer significant benefits in reducing the burden of cardiovascular diseases.
Most relevant research papers on this topic